Off Label Marketing of Medicines
Author: Public Library of Science
Peer-Reviewed Publication: N/A
Jump to: Main Digest | Publications
Synopsis: Despite FDA regulation of the approval and use of pharmaceutical products off-label marketing of drugs has occurred in all aspects of the US health care system. Off-label marketing of medicines in the US is rife but difficult to control.
Off-label marketing of medicines in the US is rife but difficult to control.
This article is from our digest of publications relating to Pharmaceutical Information that also includes:
Despite Federal Drug Administration regulation of the approval and use of pharmaceutical products, "off-label" marketing of drugs (for purposes other than those for which the drug was approved) has occurred in all aspects of the US health care system. In a study published in this week's PLoS Medicine, Aaron S. Kesselheim from Brigham and Women's Hospital, Boston, USA and colleagues report that the most common alleged off-label marketing practices also appear to be the most difficult to control through external regulatory approaches. They identified three main goals of alleged off-label marketing programs: expansion of drug use to unapproved diseases, expansion to unapproved disease subtypes, and expansion to unapproved drug dosing strategies, typically higher doses.
In their study, the authors classified the strategies and practices used in off-label marketing by examining 41 complaints filed by whistle-blowers related to 18 alleged cases of off-label marketing in federal fraud cases that were settled or unsealed between January 2004 and October 2010. These findings provide a snapshot of off-label marketing strategies and practices allegedly employed in the US, and this analysis may help to develop new and effective regulatory strategies.
All of the whistle-blowers alleged prescriber-related practices (including providing financial incentives and free samples to physicians), and most alleged internal practices intended to bolster off-label marketing, such as sales quotas that could only be met if the manufacturer's sales representatives promoted off-label drug use. Payer-related practices (for example, discussions with prescriber's about ways to ensure insurance reimbursement for off-label prescriptions) and consumer-related practices (most commonly, the review of confidential patient charts to identify consumers who could be off-label users) were also alleged. However, these practices were alleged by whistle-blowers in cases intervened by the US Department of Justice, and were not the subject of testimony in a full trial; thus, some of the practices identified by the researchers could not be confirmed.
The authors say: "Off-label marketing has been ubiquitous in the health care system and features some behaviors and strategies that may be resistant to external regulatory approaches."
They continue: "Aside from sales representatives and other company insiders, who play important roles as whistle-blowers, physicians are alone in having a full view of many of the most insidious forms of illegal marketing outlined in the complaints we reviewed. As physicians' understanding of these practices and the consequences of inappropriate off-label promotion for public health evolves, so may their enthusiasm for shutting them down."
Funding: ASK is supported by a career development award from the Agency for Healthcare Research & Quality (K08HS18465-01), and a Robert Wood Johnson Foundation Investigator Award in Health Policy Research. MMM is supported by the Greenwall Faculty Scholars Program in Bioethics. DMS is supported by a Federation Fellowship from the Australian Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: ASK reports consulting for the Alosa Foundation, a non-profit organization that runs the Independent Drug Information Service and is not affiliated in any way with any pharmaceutical company. From 2008, ASK served as an expert witness for the state of Texas in a lawsuit against Merck related to improper promotion of rofecoxib (Vioxx). From 2007, ASK helped develop an educational program to encourage evidence-based prescribing, with funding from a grant derived from the settlement of a fraud case regarding improper promotion of gabapentin (Neurontin).
Citation: Kesselheim AS, Mello MM, Studdert DM (2011) Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistle-blower Complaints. PLoS Med 8(4): e1000431. doi:10.1371/journal.pmed.1000431
Disabled World is an independent disability community established in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative news, reviews, sports, stories and how-tos. You can also connect with us on Twitter and Facebook or learn more about Disabled World on our about us page.
Disabled World provides general information only. The materials presented are never meant to substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Financial support is derived from advertisements or referral programs, where indicated. Any 3rd party offering or advertising does not constitute an endorsement.
• Cite This Page (APA): Public Library of Science. (2011, April 7). Off Label Marketing of Medicines. Disabled World. Retrieved October 2, 2022 from www.disabled-world.com/medical/pharmaceutical/off-label.php
• Permalink: <a href="https://www.disabled-world.com/medical/pharmaceutical/off-label.php">Off Label Marketing of Medicines</a>